Kohlberg Kravis Roberts & Co. L.P. Bridge Bio Pharma, Inc. Transaction History
Kohlberg Kravis Roberts & Co. L.P.
- $1.79 Billion
- Q3 2024
A detailed history of Kohlberg Kravis Roberts & Co. L.P. transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Kohlberg Kravis Roberts & Co. L.P. holds 25,260,971 shares of BBIO stock, worth $669 Million. This represents 35.94% of its overall portfolio holdings.
Number of Shares
25,260,971
Previous 31,060,971
18.67%
Holding current value
$669 Million
Previous $787 Million
18.26%
% of portfolio
35.94%
Previous 45.4%
Shares
4 transactions
Others Institutions Holding BBIO
# of Institutions
290Shares Held
170MCall Options Held
10.4MPut Options Held
2.37M-
Viking Global Investors LP25.1MShares$665 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.2MShares$376 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$330 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$161 Million63.58% of portfolio
-
State Street Corp Boston, MA5.96MShares$158 Million0.01% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $3.93B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...